{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}],"title":"Improvement by at least 1 grade per CTCAE scale"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Did not respond to colesevelam treatment"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"To evaluate the ability of colesevelam to improve lenalidomide-associated diarrhea in participants with multiple myeloma treated with lenalidomide maintenance. Diarrhea will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) grading. The primary end-point is improvement of diarrhea to grade 1 or better according to the CTCAE 5.0 scale by 4 weeks of treatment with colesevelam.","groups":[{"description":"Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea","id":"OG000","title":"Participants With Myeloma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Number of Participants With Improvement of Lenalidomide-associated Diarrhea Evaluated by CTCAE 5.0","type":"PRIMARY","unitOfMeasure":"Participants"}